Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | CBLB | Q13191 | 1/20 | 0.32 |
| ▸ | ULK1 | O75385 | 1/20 | 0.30 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437919 | 0.89 | ULK1 (0.35) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL19437920 | 0.89 | ULK1 (0.35) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL19438108 | 0.89 | ULK1 (0.35) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL23901683 | 0.84 | CD38 (0.35) | MAPK1 | |
| SCHEMBL19438038 | 0.81 | ACACB (0.35) | ACACBULK1ULK2MKNK2STK17A | |
| SCHEMBL19438216 | 0.80 | JAK2 (0.36) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL19438295 | 0.78 | JAK2 (0.39) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL19449590 | 0.78 | ULK1 (0.34) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL19449397 | 0.78 | PDE2A (0.36) | ULK1ULK2MKNK2STK17AMAPK1 | |
| SCHEMBL19438052 | 0.78 | RORC (0.34) | ACACBULK1ULK2MKNK2STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | ACACB 2039/4885CBLB 2558/4885ULK1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.